Literature DB >> 1969888

Federal and state regulation of opioids.

D E Joranson.   

Abstract

Federal and state policy governing opioids is discussed in relation to achieving balance between efforts to control drug abuse and maintain drug availability for legitimate medical purposes. Federal controlled substances law affirms the essential medical value of many drugs that are controlled substances, and states that opioids may be used for extended periods in treatment of patients with intractable pain. Providing opioids to addicts is otherwise unlawful unless the physician is separately registered to treat addiction. State laws, while they permit prescribing of opioids for pain, do not provide affirmative recognition of the medical value of controlled substances. Imprecise legal definition of terms allows patients to be confused with addicts. In addition, some states require physicians to report opioid-dependent patients to the government, regulate prescribing of Schedule II opioids more strictly, and limit the quantity of controlled substances that may be prescribed at one time. Recommendations are offered to revise state laws and to improve communication between health care professionals and regulators.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969888

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  2 in total

1.  De facto long-term opioid therapy for noncancer pain.

Authors:  Michael Von Korff; Michael Von Korff; Kathleen Saunders; Gary Thomas Ray; Denise Boudreau; Cynthia Campbell; Joseph Merrill; Mark D Sullivan; Carolyn M Rutter; Michael J Silverberg; Caleb Banta-Green; Constance Weisner
Journal:  Clin J Pain       Date:  2008 Jul-Aug       Impact factor: 3.442

2.  A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity.

Authors:  Paul R Chelminski; Timothy J Ives; Katherine M Felix; Steven D Prakken; Thomas M Miller; J Stephen Perhac; Robert M Malone; Mary E Bryant; Darren A DeWalt; Michael P Pignone
Journal:  BMC Health Serv Res       Date:  2005-01-13       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.